Remimazolam for Bronchoscopy in High-Risk Patients

Condition(s) studied

Investigational drug(s) / intervention(s)

propofol and alfentanil: General anesthesia with spontaneous breathing maintained is administered using propofol and alfentanil.

remimazolam combined with propofol and alfentanil: General anesthesia with spontaneous breathing maintained is administered using remimazolam combined with propofol and alfentanil.

Study summary

Bronchoscopy is currently widely used for the diagnosis and treatment of various respiratory diseases. However, the operation of bronchoscopy is irritating, causes a strong stress response, and shares the airway with the patient, making the patient highly susceptible to respiratory and cardiovascular risks. Among these risks, hypoxia is the most common adverse event.Different drug regimens can be selected for anesthesia under deep sedation. The combination of analgesic agents can help reduce coughing during bronchoscopy. Therefore, we employ a combination of sedative and analgesic drugs for painless bronchoscopy procedures. Among sedatives, propofol is the most commonly used. However, due to its disadvantages, such as respiratory and circulatory depression, we have introduced a novel approach combining remimazolam for sedation. The aim is to investigate whether this new regimen, compared to traditional propofol-based sedation, can reduce the incidence of hypoxia, minimize circulatory depression, and lead to faster postoperative awakening and recovery. Additionally, we hope to observe fewer adverse events, such as perioperative nausea and vomiting, excessive secretions, dizziness, and chills.

Eligibility

Primary outcome measure(s)

• The incidence of hypoxia（75% ≤ SpO2 < 90% for <60 s） — Periprocedural

Trial sites (2)

More First Affiliated Hospital of Zhejiang University trials in China

Other trials for the same condition